Neovasc Inc. has received $-0.08 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 27.27%.
Neovasc Inc. results fell short with a surprise EPS of -100% or $-0.06. The Actual EPS was $-0.12 compared to the Estimated EPS of $-0.06 during its most recent quarterly earnings.
In the last quarter, Neovasc Inc. reported Annual Earnings of $-0.12. Based on the filings, last years Annual Earnings was, $-0.41. In the last Quarter, NVCN reported a surprise Earnings per Share of -100% . The consensus estimate for current quarter is $-0.08 and for the current fiscal year, the estimate is $-1.42. For the Next fiscal year, the estimate is $-0.36 based on the consensus.
Neovasc Inc. (NASDAQ:NVCN) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.13 points or 10.16% at $1.15 with 1,608,428 shares getting traded. Post opening the session at $1.3, the shares hit an intraday low of $1.14 and an intraday high of $1.37 and the price was in this range throughout the day. The company has a market cap of $90 million and the number of outstanding shares has been calculated to be 78,683,345 shares. The 52-week high of Neovasc Inc. (NASDAQ:NVCN) is $4.68 and the 52-week low is $0.37.
Neovasc Inc. is a specialty medical device company. It develops, manufactures and markets products for the cardiovascular marketplace. The Companys products include the Tiara (TM) mitral valve prosthesis in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer (TM) for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Neovasc Inc. is headquartered in Richmond, Canada.